The anti-CCR4 antibody mogamulizumab was recently developed [39, 40] and several therapeutic strategies are currently being tested, including immunostimulants, such as interferon and anti-PD-1/PDL-1 antibodies.…
Thus, targeting AKT with CTD may partially induce apoptosis via DNA damage, in contrast to previous reports stating that AKT fails to cause DNA damage…